Mounjaro for
Menopause Weight Loss

Mounjaro is approved for weight management in individuals with obesity or those who are overweight with related health conditions. This means that if a woman is going through peri-menopause or menopause and meets the criteria for weight management, Mounjaro may be prescribed as part of an overall treatment plan, but it is not indicated solely because of menopausal status. As always, any treatment decision should be made in consultation with a weight management prescriber.

The losses experienced with Mounjaro weight loss injections can vary among individuals. Clinical trials have demonstrated significant weight loss of up to 20% of body weight. Factors such as starting weight, diet, and physical activity all play a role in the effectiveness of the treatment. Some clients may start to see weight loss within a few weeks of starting Mounjaro 2.5mg. However, consistent and sustained weight loss typically occurs over several months of therapy as the dose is gradually increased through the titration process.

Common side effects of Mounjaro may include decreased appetite, nausea, constipation, diarrhoea, and abdominal discomfort. Certain GLP-1 triggers, such as large meals, greasy food, spicy food, and fizzy drinks, may exacerbate or cause these symptoms. These side effects are typically mild to moderate and tend to improve over time.

Mounjaro is a prescription medication and should only be used under the supervision of a weight loss prescriber, with medicine provided from a GPHC (general pharmaceutical council) registered Pharmacy. Mounjaro is intended for long-term use as part of a comprehensive weight management plan. Your healthcare provider will monitor your progress and determine the appropriate duration of treatment based on your individual needs and goals, potentially considering maintenance treatment.